Praziquantel as the gold standard of schistosomiasis control Drug delivery and Nanotechnological strategies

Rokaya Omar Amara, Sakina Salem Saadawi

Abstract


The poor rate of drug discovery for the control of Neglected tropical diseases (NTDs) including schistosomiasis has necessitated effective management of existing drugs by modulating their delivery. Nanotechnology-based colloidal drug carriers have been explored to improve the activity and safety profile of drugs for NTDs including parasitic diseases. In developing new drug delivery systems for schistosomiasis, research efforts have focused mainly on Praziquantel (PZQ) as the sole antischistosomal agent in current clinical practice. Carrier systems of the polymer, inorganic and lipid-based type have been investigated for the delivery of PZQ. However, promising results were obtained using lipid-based delivery systems including liposomes, solid lipid nanoparticles, nanostructured lipid carriers and nanoemulsions. Selection of these lipid carrier systems has been based on the lipophilicity of PZQ, controlled drug release, potential increase in its bioavailability by promoting lymphatic absorption to bypass the extensive first pass effect biodistribution to the host liver and enhancement of PZQ interaction with the worm tegument of a similar phospholipid nature. 


Keywords


Nanotechnology, Praziquantel, Drug delivery systems, Schistosomiasis

Full Text:

PDF

References


Li Yang Y.G., 2008. Enhancement the oral bioavailability of praziquantel by incorporation into solid lipid nanoparticles. Pharmazie 64: 86–89

Alsaqabi S.M., Lotfy W.M., 2014. Praziquantel: A Review. J Veterinar Sci Technol 5: 200.

Meister I., Ingram-Sieber K., Cowan N., Todd M., Robertson M.N., Meli C., Patra M., Gasser G., Keiser J., 2014. Activity of praziquantel enantiomers and main metabolites against Schistosoma mansoni. Antimicrob Agents Chemother 58: 5466-72.

Doenhoff Michael, J., Pica-Mattoccia, Livia, 2006. Praziquantel for the treatment of schistosomiasis: its use for control in areas with endemic disease and prospects for drug resistance. Expert Review of Anti-infective Therapy 4: 199-210.

Gray D.J., Ross A.G., Li Y.S., McManus D.P., 2011. Diagnosis and management of schistosomiasis. BMJ 342: d2651.

Wu W. Huang Y., 2013. Application of praziquantel in schistosomiasis japonica control strategies in China. Parasitol Res 112: 909–15.

Cioli D., Pica-Mattoccia L., Basso A., Guidi A., 2014. Schistosomiasis control: praziquantel forever?. Mol Biochem Parasitol 195(1): 23-9.

Coulibaly J.T., N’gbesso Y.K., Knopp S., Keiser J.N., Goran E.K., Utzinger J., 2012. Efficacy and safety of praziquantel in preschool-aged children in an area co-endemic for Schistosoma mansoni and S. haematobium. PLoS Negl Trop Dis 6: e1917.

Sousa-Figueiredo J.C., Betson M., Atuhaire A., Arinaitwe M., Navaratnam A.M., Kabatereine N.B., 2012. Performance and safety of praziquantel for treatment of intestinal schistosomiasis in infants and preschool children. PLoS Negl Trop Dis 6: e1864.

Gryseels B., Polman K., Clerinx J., Kestens L., 2006. Human schistosomiasis. Lancet 368: 1106-18.

Organization, W.H., 2006. Preventive chemotherapy in human helminthiasis. World Health Organization, Geneva, Switzerland. http://whqlibdoc.who.int/publications/2006/9241547103_eng.pdf?ua_1.

Doenhoff M.J., Hagan P., Cioli D., Southgate V., Pica-Mattoccia L., Botros S., Coles G., Tchuem Tchuenté L.A., Mbaye A., Engels D., 2009. Praziquantel: its use in control of schistosomiasis in sub-Saharan Africa and current research needs. Parasitology 136: 1825-1835.

Becker B.M.H., Andrews P., Thomas H., Eckert J., 1980. Light and electron microscopic studies on the effect of praziquantel on Schistosoma mansoni, Dicrocoelium dendriticum, and Fasciola hepatica (Trematoda) in vitro. Z Parasitenkd 63: 113-128.

Mehlhorn H., Becker B., Andrews P., Thomas H., Frenkel J.K., 1981. In vivo and in vitro experiments on the effects of praziquantel on Schistosoma mansoni. A light and electron microscopic study. Arzneimittelforschung 31: 544-554.

Redman C.A., Robertson A., Fallon P.G., Modha J., Kusel J.R., 1996. Praziquantel: an urgent and exciting challenge. Parasitol Today 12: 14-20.

Harnett W., 1988. The anthelmintic action of praziquantel. Parasitol Today 4: 144-6.

Chappuis F., Udayraj N., Stietenroth K., Meussen A., Bovier P.A., 2005. Eflornithine is safer than melarsoprol for the treatment of second-stage Trypanosoma brucei gambiense human African trypanosomiasis. Clin Infect Dis 41: 748-51.

Valencia C.I., Catto B.A., Webster L.T., Jr., Barcelon E., Ofendo-Reyes R., 1994. Concentration time course of praziquantel in Filipinos with mild Schistosoma japonicum infection. Southeast Asian J Trop Med Public Health 25: 409-14.

Mandour M.E., el Turabi H., Homeida M.M., el Sadig T., Ali H.M., Bennett J.L., Leahey W.J., Harron D.W., 1990. Pharmacokinetics of praziquantel in healthy volunteers and patients with schistosomiasis. Trans R Soc Trop Med Hyg 84: 389-93.

González-Esquivel D., Rivera J., Castro N., Yepez-Mulia L., Jung Cook H., 2005. In vitro characterization of some biopharmaceutical properties of praziquantel. Int J Pharm 295: 93-99.

Castro N., Medina R., Sotelo J., Jung H., 2000. Bioavailability of praziquantel increases with concomitant administration of food. Antimicrob Agents Chemother 44: 2903-4.

Li X.Q., Björkman A., Andersson T.B., Gustafsson L.L., Masimirembwa C.M., 2003. Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol 59: 429-442.

Masimirembwa C.M. Hasler J.A., 1994. Characterisation of praziquantel metabolism by rat liver microsomes using cytochrome P450 inhibitors. Biochem Pharmacol 48: 1779-1783.

Chaud M.V., Tamascia P., Cristina de Lima A., Paganelli M.O., Gremião M.P.D., de Freitas O., 2010. Solid dispersions with hydrogenated castor oil increase solubility, dissolution rate and intestinal absorption of praziquantel. Braz J Pharm Sci 46: 473-481.

Melo A.J.B., Iamamoto Y., Maestrin A.P.J., Smith J.R.L., Santos M.A., Lopes N.P., Bonato P.S., 2005. Biomimetic oxidation of praziquantel catalysed by metalloporphyrins. J Mol Catal A: Chem 226: 23-31.

Cioli D. Pica-Mattoccia L., 2003. Praziquantel. Parasitol Res 90: 53-59.

Deribew K. Petros B., 2013. Efficacy of praziquantel for the treatment of schistosomiasis in Ethiopia. Int J Med Medical Sci 5: 131-139.

Olliaro P., Delgado-Romero P., Keiser J., 2014. The little we know about the pharmacokinetics and pharmacodynamics of praziquantel (racemate and R-enantiomer). J Antimicrob Chemother 69: 863-870.

Hotez P.J., Molyneux D.H., Fenwick A., Ottesen E., Ehrlich S., Sachs J.D., 2006. "Incorporating a rapid-impact package for neglected tropical diseases with programs for HIV/AIDS, tuberculosis, and malaria.". PLoS Med 3: e102.

Crompton, David W. T., World Health Organization. 2006‎. Preventive chemotherapy in human helminthiasis : coordinated use of anthelminthic drugs in control interventions : a manual for health professionals and programme managers. World Health Organization. https://apps.who.int/iris/handle/10665/43545

Lemoine J.F., Desormeaux A.M., Monestime F., Fayette C.R., Desir L., Direny A.N., Carciunoiu S., Miller L., Knipes A., Lammie P., Smith P., Stockton M., Trofimovich L., Bhandari K., Reithinger R., Crowley K., Ottesen E., Baker M., 2016. Controlling Neglected Tropical Diseases (NTDs) in Haiti: Implementation Strategies and Evidence of Their Success. PLoS Negl Trop Dis 10: e0004954. https://doi.org/10.1371/journal.pntd.0004954

Mishra A., Vuddanda P.R., Singh S., 2014. Intestinal lymphatic delivery of praziquantel by solid lipid nanoparticles: Formulation Design, In Vitro and In Vivo Studies. J Nanotech. doi.org/10.1155/2014/351693.

Xiao S.H., Catto B.A., Webster L.T., 1985. Effects of praziquantel on different developmental stages of Schistosoma mansoni in vitro and in vivo. J Infect Dis 151: 1130-7.

Gryseels B., Mbaye A., De Vlas S., Stelma F.F., Guisse F., Van Lieshout F.D., Diop M., Ly A., Tchuem-Tchuente L.A., Engels D., Polman, K., 2001. Are poor responses to praziquantel for the treatment of Schistosoma mansoni infections in Senegal due to resistance?. Trop Med Int Health 6: 864-873.

Frezza T.F., Gremiao M.P., Zanotti-Magalhaes E.M., Magalhaes L.A., de Souza A.L., Allegretti S.M., 2013. Liposomal-praziquantel: efficacy against Schistosoma mansoni in a preclinical assay. Acta Trop 128: 70-5.

Vimieiro A.C.S., Araújo N., Katz N., Kusel, J.R., Coelho P.M.Z., 2013. Schistogram changes after administration of antischistosomal drugs in mice at the early phase of Schistosoma mansoni infection. Mem Inst Oswaldo Cruz 108: 881-886.

Doenhoff M.J., Kusel J.R., Coles G.C., Cioli D., 2002. Resistance of Schistosoma mansoni to praziquantel: is there a problem?. Trans R Soc Trop Med Hyg 96: 465-469.

Fallon P.G., Tao L.F., Ismail M.M., Bennett J.L., 1996. Schistosome resistance to praziquantel: Fact or artifact?. Parasitol Today 12: 316-20.

Gryseels B., Stelma F.F., Talla I., van Dam G.J., Polman K., Sow S., Diaw M., Sturrock R.F., Doehring-Schwerdtfeger E., Kardorff R., 1994. Epidemiology, immunology and chemotherapy of Schistosoma mansoni infections in a recently exposed community in Senegal. Trop Geogr Med 46:209-19.

Castillo-Chavez C., Feng Z., Xu D., 2008. A schistosomiasis model with mating structure and time delay. Math Biosci 211: 333-41.

Messerli S.M., Kasinathan R.S., Morgan W., Spranger S., Greenberg R.M., 2009. Schistosoma mansoni P-glycoprotein levels increase in response to praziquantel exposure and correlate with reduced praziquantel susceptibility. Mol Biochem Parasitol 167: 54-9.

Qi L., Cui, J., 2013. A Schistosomiasis Model with Praziquantel Resistance. Discrete Dyn Nat Soc. doi:10.1155/2013/945767. https://doi.org/10.1155/2013/945767.

Di Masi J.A., Hansen R.W., Grabowski H.G., 2003. The price of innovation: new estimates of drug development costs. J Health Econ 22: 151-85.

Hopkins A.L., Witty M.J., Nwaka S.,2007. Neglected Diseases Mission possible. Nature 449: 166-169.

Pedrique B., Strub-Wourgaft N., Some C., Olliaro P., Trouiller P., Ford N., Pecoul B., Bradol, J.H., 2013. The drug and vaccine landscape for neglected diseases (2000-11): a systematic assessment. Lancet Glob Health 1: e371-9.

Sayed AA, S.A., Thomas CJ, Inglese J, Austin CP, Williams DL., 2008. Identification of oxadiazoles as new drug leads for the control of schistosomiasis. Nat Med 14: 407-412.

Saudi M.N.S., Youssef A.Y., Badr M.H., EL-azzouni M.Z., Mossallam S.F., Baddour N.M., Eissa M.M., 2009. Synthesis of subsituted pyrimidinedione derivatives as potential schistosomicidal agents. Lett Drug Des Discov 6: 268-277.

Botros S.S., William S., Beadle J.R., Valiaeva N., Hostetler, K.Y., 2009. Antischistosomal activity of hexadecyloxypropyl cyclic 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine and other alkoxyalkyl esters of acyclic nucleoside phosphonates assessed by schistosome worm killing in vitro. Antimicrob Agents Chemother 53: 5284-7.

Neves J.K., Botelho S.P., de Melo C.M., Pereira V.R., de Lima Mdo C., Pitta Ida R., Albuquerque M.C., Galdino S.L., 2010. Biological and immunological activity of new imidazolidines against adult worms of Schistosoma mansoni. Parasitol Res 107: 531-8.

Roszkowskia P., Maurin J.K., Czarnocki Z., 2006. Enantioselective synthesis of (R)-(−)-praziquantel (PZQ). Tetrahedron: Asymmetry 17: 1415-1419.

Ma C., Zhang Q.F., Tan Y.B., Wang L., 2004. Total synthesis of (-)-praziquantel: an anthelmintic drug. J Chem Res 186-187.

Meyer T., Sekljic H., Fuchs S., Bothe H., Schollmeyer D., Miculka, C., 2009. Taste, a new incentive to switch to (R)-praziquantel in schistosomiasis treatment. PLoS Negl Trop Dis 3: e357.

Berriman M., Haas B.J., LoVerde P.T., Wilson R.A., Dillon G.P., Cerqueira G.C., Mashiyama S.T., Al-Lazikani B., Andrade L.F., Ashton P.D., Aslett M.A., Bartholomeu D.C., Blandin G., Caffrey C.R., Coghlan A., Coulson R., Day T.A., Delcher A., DeMarco R., Djikeng A., Eyre T., Gamble J.A., Ghedin E., Gu Y., Hertz-Fowler C., Hirai H., Hirai Y., Houston R., Ivens A., Johnston D.A., Lacerda D., Macedo C.D., McVeigh P., Ning Z., Oliveira G., Overington J.P., Parkhill J., Pertea M., Pierce R.J., Protasio A.V., Quail M.A., Rajandream M.A., Rogers J., Sajid M., Salzberg S.L., Stanke M., Tivey A.R., White O., Williams D.L., Wortman J., Wu W., Zamanian M., Zerlotini A., Fraser-Liggett C.M., Barrell B.G., El-Sayed N.M., 2009. The genome of the blood fluke Schistosoma mansoni. Nature 460: 352-8.

Young N.D., Jex A.R., Li B., Liu S., Yang L., Xiong Z., Li Y., Cantacessi C., Hall R.S., Xu X., Chen F., Wu X., Zerlotini A., Oliveira G., Hofmann A., Zhang G., Fang X., Kang Y., Campbell B.E., Loukas A., Ranganathan S., Rollinson D., Rinaldi G., Brindley P.J., Yang H., Wang J., Wang J., Gasser R.B., 2012. Whole-genome sequence of Schistosoma haematobium. Nat Genet 44: 221-5.

Cabezas-Cruz A., Lancelot J., Caby S., Oliveira G., Pierce R.J., 2014. Epigenetic control of gene function in schistosomes: a source of therapeutic targets?. Front Genet 5: 317.

Arrowsmith C.H., Bountra C., Fish P.V., Lee K., Schapira M., 2012. Epigenetic protein families: a new frontier for drug discovery. Nat Rev Drug Discov 11: 384-400.

de Moraes J., 2012. Antischistosomal Natural Compounds: Present Challenges for New Drug Screens, in Current Topics in Tropical Medicine, D.A. Rodriguez-Morales, Editor. InTech, DOI: 10.5772/27740. Available from: https://www.intechopen.com/books/current-topics-in-tropical-medicine/antischistosomal-natural-compounds-present-challenges-for-new-drug-screens.

Swinney D.C. Anthony J., 2011. How were new medicines discovered? . Nat Rev Drug Discov 10: 507-519.

Neves B.J., Andrade C.H., Cravo P.V., 2015. Natural products as leads in schistosome drug discovery. Molecules 20: 1872-1903.

Crump A., 2017. Ivermectin: enigmatic multifaceted 'wonder' drug continues to surprise and exceed expectations. J Antibiot (Tokyo) 70: 495-505.

Xiao S., Tanner M., N'Goran E.K., Utzinger J., Chollet J., Bergquist R., Chen M., Zheng J., 2002. Recent investigations of artemether, a novel agent for the prevention of schistosomiasis japonica, mansoni and haematobia. Acta Trop 82: 175-81.

Utzinger J., Xiao S.H., Tanner M., Keiser J., 2007. Artemisinins for schistosomiasis and beyond. Curr Opin Investig Drugs 8: 105-16.

de Melo N.I., Magalhaes L.G., de Carvalho C.E., Wakabayashi K.A., de P.A.G., Ramos R.C., Mantovani A.L., Turatti I.C., Rodrigues V., Groppo M., Cunha W.R., Veneziani R.C., Crotti A.E., 2011. Schistosomicidal activity of the essential oil of Ageratum conyzoides L. (Asteraceae) against adult Schistosoma mansoni worms. Molecules 16: 762-73.

Yousif F., Hifnawy M.S., Soliman G., Boulos L., Labib T., Mahmoud S., El-Hallouty S.M., El-Gendy M., Gohar L., El-Manawaty M., Fayyad W., El-Menshawi B., 2007. Large-scale in Vitro. Screening of Egyptian Native and Cultivated Plants for Schistosomicidal Activity. Pharmaceut Biol 45: 501-510.

El Ridi R.A.F. Tallima H.A.-M., 2013. Novel therapeutic and prevention approaches for schistosomiasis: Review. J Adv Res 4: 467-478.

Badria F., Abou-Mohamed G., El-Mowafy A., Masoud A., Salama O., 2001. Mirazid: A New Schistosomicidal Drug. Pharm Biol 39: 127-131.

Osman M.M., El-Taweel H.A., Shehab A.Y., Farag H.F., 2010. Ineffectiveness of myrrh-derivative Mirazid against schistosomiasis and fascioliasis in humans. East Mediterr Health J 16: 932-6.

El Ridi R., Aboueldahab M., Tallima H., Salah M., Mahana N., Fawzi S., Mohamed S.H., Fahmy O.M., 2010. In vitro and in vivo activities of arachidonic acid against Schistosoma mansoni and Schistosoma haematobium. Antimicrob Agents Chemother 54: 3383-9.

Selim S., El Sagheer O., El Amir A., Barakat R., Hadley K., Bruins M.J., El Ridi R., 2014. Efficacy and safety of arachidonic acid for treatment of Schistosoma mansoni-infected children in Menoufiya, Egypt. Am J Trop Med Hyg 91: 973-81.

Dkhil M.A., Bauomy A.A., Diab M.S.M., Al-Quraishy S., 2016. Protective role of selenium nanoparticles against Schistosoma mansoni induced hepatic injury in mice. Biomed Res 27: 214-219.

Dkhil M.A., Bauomy A.A., Diab M.S., Al-Quraishy S., 2015. Antioxidant and hepatoprotective role of gold nanoparticles against murine hepatic schistosomiasis. Int J Nanomedicine 10: 7467-75.

Dkhil M.A., Bauomy A.A., Diab M.S., Wahab R., Delic D., Al-Quraishy S., 2015. Impact of gold nanoparticles on brain of mice infected with Schistosoma mansoni. Parasitol Res 114(10): 3711-9.

Panic G., Duthaler U., Speich B., Keiser J., 2014. Repurposing drugs for the treatment and control of helminth infections. Int J Parasitol Drugs Drug Resist 4(3): 185-200.

Panic G., Vargas M., Scandale I., Keiser J., 2015. Activity Profile of an FDA-Approved Compound Library against Schistosoma mansoni. PLoS Negl Trop Dis 9: e0003962.

Cowan N. Keiser J., 2015. Repurposing of anticancer drugs: in vitro and in vivo activities against Schistosoma mansoni. Parasit Vectors 8: 417.

Marek M., Kannan S., Hauser A.T., Moraes Mourao M., Caby S., Cura V., Stolfa D.A., Schmidtkunz K., Lancelot J., Andrade L., Renaud J.P., Oliveira G., Sippl W., Jung M., Cavarelli J., Pierce R.J., Romier C., 2013. Structural basis for the inhibition of histone deacetylase 8 (HDAC8), a key epigenetic player in the blood fluke Schistosoma mansoni. PLoS Pathog 9: e1003645.

Oliveira G., 2014. Cancer and parasitic infections: similarities and opportunities for the development of new control tools. Rev Soc Bras Med Trop 47: 1-2.

Eissa M.M., El-Azzouni M.Z., Amer E.I., Baddour N.M., 2011. Miltefosine, a promising novel agent for schistosomiasis mansoni. Int J Parasitol 41: 235-42.

Eissa M.M., El-Bardisy S., Tadros M., 2011. Bioactivity of miltefosine against aquatic stages of Schistosoma mansoni, Schistosoma haematobium and their snail hosts supported by Scanning Electron Microscopy. Parasit Vectors 4: 73.

Staff P.O., 2015. Erratum: In vitro and in vivo anti-schistosomal activity of the alkylphospholipid analog edelfosine. PLoS One 10: e0123149.

Abaza S.M., 2016. Applications of nanomedicine in parasitic diseases. Parasitologists United J 9: 1-6.

Date A.A., Joshi M.D., Patravale V.B., 2007. Parasitic diseases: Liposomes and polymeric nanoparticles versus lipid nanoparticles. Adv Drug Deliv Rev 59: 505-21.

Islan G.A., Duran M., Cacicedo M.L., Nakazato G., Kobayashi R.K., Martinez D.S., Castro G.R., Duran N., 2017. Nanopharmaceuticals as a solution to neglected diseases: Is it possible?. Acta Trop 170: 16-42.

Kayser O. Kiderlen A.F., 2003. Delivery strategies for antiparasitics. Expert Opin Investig Drugs 12: 197-207.

Kayser O., Olbrich C., Croft S.L., Kiderlen A.F., 2003. Formulation and biopharmaceutical issues in the development of drug delivery systems for antiparasitic drugs. Parasitol Res 90: S63-70.

Pollastri M.P., Campbell R.K., 2011. Target repurposing for neglected diseases. Future Med Chem 3: 1307-15.

Groo A.C., Bossiere M., Trichard L., Legras P., Benoit J.P., Lagarce F., 2015. In vivo evaluation of paclitaxel-loaded lipid nanocapsules after intravenous and oral administration on resistant tumor. Nanomedicine (Lond) 10: 589-601.

Serrano D.R., Lalatsa A., Dea-Ayuela M.A., Bilbao-Ramos P.E., Garrett N.L., Moger J., Guarro J., Capilla J., Ballesteros M.P., Schatzlein A.G., Bolas F., Torrado J.J., Uchegbu I.F., 2015. Oral particle uptake and organ targeting drives the activity of amphotericin B nanoparticles. Mol Pharm 12: 420-31.

Roger E., Gimel J.C., Bensley C., Klymchenko A.S., Benoit J.P., 2017. Lipid nanocapsules maintain full integrity after crossing a human intestinal epithelium model. J Control Release 253: 11-18.

Eissa M.M., El-Moslemany R.M., Ramadan A.A., Amer E.I., El-Azzouni M.Z., El-Khordagui L.K., 2015. Miltefosine Lipid Nanocapsules for Single Dose Oral Treatment of Schistosomiasis Mansoni: A Preclinical Study. PLoS One 10: e0141788.

Mainardes R.M., Chaud M.V., Gremiao M.P., Evangelista R.C., 2006. Development of praziquantel-loaded PLGA nanoparticles and evaluation of intestinal permeation by the everted gut sac model. J Nanosci Nanotechnol 6: 3057-61.

El-Feky G.S., Mohamed W.S., Nasr H.E., El-Lakkany N.M., Seif el-Din S.H., Botros S.S., 2015. Praziquantel in a clay nanoformulation shows more bioavailability and higher efficacy against murine schistosoma mansoni infection. Antimicrob Agents Chemother 59: 3501–3508.

Xie S., Pan B., Wang M., Zhu L., Wang F., Dong Z., Wang X., Zhou W., 2010. Formulation, characterization and pharmacokinetics of praziquantel-loaded hydrogenated castor oil solid lipid nanoparticles. Nanomedicine (Lond) 5: 693-701.

Yang L., Geng Y., Li H., Zhang Y., You J., Chang Y., 2009. Enhancement the oral bioavailability of praziquantel by incorporation into solid lipid nanoparticles. Pharmazie 64: 86-89.

Akbarieh M., Besner J.G., Galal A., Tawashi R., 1992. Liposomal delivery system for the targeting and controlled release of praziquantel. Drug Develop Ind Pharm 18: 303-317.

Mourao S.C., Costa P.I., Salgado H.R.N., Gremiao M.P.D., 2005. Improvement of antischistosomal activity of praziquantel by incorporation into phosphatidylcholine-containing liposomes. Int J Pharm 295: 157-162.

Westesen K. Siekmann B., 1997. Investigation of the gel formation of phospholipid stabilized solid lipid nanoparticles". Int J Pharm 151: 35-45.

Uner M. Yener G., 2007. " Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives". Int J Nanomedicine 2: 289-300.

Joshi M.D., Müller, R.H., 2009. " Lipid nanoparticles for parenteral delivery of actives". Eur J Pharm Biopharm 71: 161-172.

Harde H., Das M., Jain S., 2011. Solid lipid nanoparticles: an oral bioavailability enhancer vehicle. Expert Opin Drug Deliv 8: 1407-24.

De Souza A.L.R., Andreani T., Nunes F.M., Cassimiro D.L., De Almeida A.E., Ribeiro C.A., Sarmento V.H.V., Gremiao M.P.D., Silva A.M., Souto E.B., 2012. Loading of praziquantel in the crystal lattice of solid lipid nanoparticles: Studies by DSC and SAXS. J Therm Anal Cal 108: 353-360.

Xie S., Pan B., Shi B., Zhang Z., Zhang X., Wang M., Zhou W., 2011. Solid lipid nanoparticle suspension enhanced the therapeutic efficacy of praziquantel against tapeworm. Int J Nanomedicine 6: 2367-74.

Muller R.H., Radtke M., Wissing S.A., 2002. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev 54: S131-55.

Muller R.H., Radtke M., Wissing S.A., 2002. Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm 242: 121-8.

Chen C.C., Tsai T.H., Huang Z.R., Fang J.Y., 2010. Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: physicochemical characterization and pharmacokinetics. Eur J Pharm Biopharm 74: 474-82.

Jenning V., Mader K., Gohla S.H., 2000. Solid lipid nanoparticles (SLN) based on binary mixtures of liquid and solid lipids: a (1)H-NMR study. Int J Pharm 205: 15-21.

Kolenyak-Santos F., Garnero C., N. de Oliveira R., R. de Souza A.L., Chorilli M., Allegretti S.M., Longhi M.R., Chaud M.V., Gremiano M.P.D., 2014. Nano-structured lipid carriers as a strategy to improve the in vitro schistosomiasis activity of praziquantel. J Nanosci Nanotech 14: 1-12.

Santos F.K., Souza A.L.R., Chaud M.V., Gremião M.P.D., Evaluation of intestinal absorption of praziquantel incorporated into nanostructured lipid carriers using the everted gut sac model.

Bouchemal K., Briançon S., Perrier E., Fessi H., 2004. Nano-emulsion formulation using spontaneous emulsification: solvent, oil and surfactant optimisation. Int J Pharm 280: 241-251.

Anton N., Benoit J.P., Saulnier P., 2008. Design and production of nanoparticles formulated from nano-emulsion templates-a review. J Control Release 128: 185-99.

de Campos V.E., Silva J.A., Ricci-Junior E., Mansur C.R., Conti D.S., da Rocha S.R., 2016. Polymeric Nanostructured Systems for Liquid Formulation of Praziquan-tel: Development and in vitro Assessment. Curr Drug Deliv 13: 287-97.

Cong Z., Shi Y., Peng X., Wei B., Wang Y., Li J., 2017. Design and optimization of thermosensitive nanoemulsion hydrogel for sustained-release of praziquantel. Drug Dev Ind Pharm 43: 558-573.

Heurtault B., Saulnier P., Pech B., Proust J.E., Benoit J.P., 2002. A novel phase inversion-based process for the preparation of lipid nanocarriers. Pharm Res 19: 875–880.

Roger E., Lagarce F., Benoit J.P., 2009. The gastrointestinal stability of lipid nanocapsules. Int J Pharm 379:260–265.

Roger E., Lagarce F., Benoit J.P., 2011. Development and characterization of a novel lipid nanocapsule formulation of Sn38 for oral administration. Eur J Pharm Biopharm 79:181–188.

Groo A.C., Saulnier P., Gimel J.C., 2013. Fate of paclitaxel lipid nanocapsules in intestinal mucus in view of their oral delivery. Int J Nanomedicine 8:4291–4302.

Amara R.O., Ramadan A.A., El-Moslemany R.M., Eissa M.M., El-Azzouni M.Z., El-Khordagui L.K., 2018. Praziquantel-lipid nanocapsules: an oral nanotherapeutic with potential Schistosoma mansoni tegumental targeting. Int J Nanomed 13:4493–4505.

Malhado M., Pinto D.P., Silva A.C.A., Silveira G.P.E., Pereira H.M., Santos J.G.F., Guilarducci-Ferraz C.V.V., Vicosa A.L., Nele M., Fonseca L.B., Pinto J.C.C.S., Calil-Elias S., 2016. Preclinical pharmacokinetic evaluation of praziquantel loaded in poly (methyl methacrylate) nanoparticle using a HPLC-MS/MS. J Pharm Biomed Anal 117: 405-412.

Mainardes, R.M., Evangelista, R.C., 2005. PLGA nanoparticles containing praziquantel: effect of formulation variables on size distribution. Int J Pharm 290: 137-44.

Mainardes R.M., Evangelista, R.C., 2005. Praziquantel-loaded PLGA nanoparticles: preparation and characterization. J Microencapsul 22: 13-24.

Fonseca l.B., Nele M., Volpato N.M., Seiceira R.C., Pinto, J.C., 2013. Production of PMMA Nanoparticles Loaded with Praziquantel Through “In Situ” Miniemulsion Polymerization. Macromol React Eng 7: 54-63.




DOI: http://dx.doi.org/10.52155/ijpsat.v31.1.4057

Refbacks

  • There are currently no refbacks.


Copyright (c) 2022 Sakina Salem Saadawi

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.